Dr. Stapleton served as Chief Technical Officer and Executive Vice President at Genocea, working to develop next generation personalized immunotherapies in the forms of vaccines and cell therapies. He joined Genocea in January 2021, bringing more than 20 years of industry experience to the company, having led technical, quality, and manufacturing operations at commercial and clinical stage biopharmaceutical companies.
Before that, he served as President and Chief Operating Officer of American Type Culture Collection (ATCC), as well as a member of the Board of Directors of both ATCC and ATCC Global.
Prior to ATCC, Dr. Stapleton worked in senior manufacturing and technical operations roles at Iovance Biotherapeutics, Inc. and Synthetic Biologics, Inc. after spending 15 years in positions of increasing responsibility in Merck and Company’s manufacturing organization.
At Merck, Dr. Stapleton led a complex science, technology, and engineering organization at a manufacturing site responsible for supporting Merck’s $5 billion annual revenue vaccine business.
Dr. Stapleton earned a bachelor’s degree in Biology from Mary Washington College in Fredericksburg, Virginia and received his Ph.D. in Microbial Ecology from the University of Tennessee, Knoxville. He has served as peer reviewer for a half dozen scientific journals, co-authored 17 peer-reviewed manuscripts, and holds multiple patents.
